First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors
ConditionSolid Tumors
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorMabwell (Shanghai) Bioscience Co., Ltd.
About this trial
This is the first-in-human study of 7MW4911 in Chinese patients, to investigate its prelimary safety and efficacy in patients with Advanced Solid Tumors.
Eligibility criteria
Qualifiers
Aged 18~75.
ECOG 0-1.
Life expectancy ≥ 3 months.
Participants with pathologically (histologically or cytologically) confirmed advanced solid tumors.
Disqualifiers
Other concurrent malignancy in the recent 3 years except for adequately treated carcinoma in situ.
Active, untreated or symptomatic CNS metastasis.
Effusions that require frequent drainage.
Patients with active autoimmune disease, except for type I diabetes, hypothyroidism and other autoimmune disease that does not require systemic treatment.
Trial design
Treatments tested in this trial
- 7MW4911
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov